NASDAQ:IDXX
Idexx Laboratories Stock Earnings Reports
$518.10
+6.11 (+1.19%)
At Close: May 16, 2025
IDEXX Laboratories Earnings Calls
Q1 2025
Beat
$2.96 (3.86%)
Release date | May 01, 2025 |
EPS estimate | $2.85 |
EPS actual | $2.96 |
EPS Surprise | 3.86% |
Revenue estimate | 997.098M |
Revenue actual | 998.427M |
Revenue Surprise | 0.133% |
Q4 2024
Beat
$2.62 (9.62%)
Release date | Feb 03, 2025 |
EPS estimate | $2.39 |
EPS actual | $2.62 |
EPS Surprise | 9.62% |
Revenue estimate | 935.147M |
Revenue actual | 954.288M |
Revenue Surprise | 2.05% |
Q3 2024
Beat
$2.80 (4.48%)
Release date | Oct 31, 2024 |
EPS estimate | $2.68 |
EPS actual | $2.80 |
EPS Surprise | 4.48% |
Revenue estimate | 980.319M |
Revenue actual | 975.543M |
Revenue Surprise | -0.487% |
Q2 2024
Beat
$3.02 (4.86%)
Release date | Aug 06, 2024 |
EPS estimate | $2.88 |
EPS actual | $3.02 |
EPS Surprise | 4.86% |
Revenue estimate | 1.007B |
Revenue actual | 1.004B |
Revenue Surprise | -0.305% |
Last 4 Quarters for IDEXX Laboratories
Below you can see how IDXX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Beat
Release date | Aug 06, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $469.37 |
EPS estimate | $2.88 |
EPS actual | $3.02 |
EPS surprise | 4.86% |
Date | Price |
---|---|
Jul 31, 2024 | $476.12 |
Aug 01, 2024 | $477.84 |
Aug 02, 2024 | $468.63 |
Aug 05, 2024 | $455.08 |
Aug 06, 2024 | $469.37 |
Aug 07, 2024 | $467.07 |
Aug 08, 2024 | $483.91 |
Aug 09, 2024 | $482.84 |
Aug 12, 2024 | $479.93 |
4 days before | -1.42% |
4 days after | 2.25% |
On release day | -0.490% |
Change in period | 0.80% |
Q3 2024
Beat
Release date | Oct 31, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $406.92 |
EPS estimate | $2.68 |
EPS actual | $2.80 |
EPS surprise | 4.48% |
Date | Price |
---|---|
Oct 25, 2024 | $451.41 |
Oct 28, 2024 | $449.44 |
Oct 29, 2024 | $447.83 |
Oct 30, 2024 | $451.08 |
Oct 31, 2024 | $406.92 |
Nov 01, 2024 | $417.28 |
Nov 04, 2024 | $414.52 |
Nov 05, 2024 | $415.98 |
Nov 06, 2024 | $423.42 |
4 days before | -9.86% |
4 days after | 4.05% |
On release day | 2.55% |
Change in period | -6.20% |
Q4 2024
Beat
Release date | Feb 03, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $469.04 |
EPS estimate | $2.39 |
EPS actual | $2.62 |
EPS surprise | 9.62% |
Date | Price |
---|---|
Jan 28, 2025 | $417.86 |
Jan 29, 2025 | $418.75 |
Jan 30, 2025 | $423.99 |
Jan 31, 2025 | $422.05 |
Feb 03, 2025 | $469.04 |
Feb 04, 2025 | $465.03 |
Feb 05, 2025 | $468.55 |
Feb 06, 2025 | $460.56 |
Feb 07, 2025 | $459.78 |
4 days before | 12.25% |
4 days after | -1.97% |
On release day | -0.85% |
Change in period | 10.03% |
Q1 2025
Beat
Release date | May 01, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $471.38 |
EPS estimate | $2.85 |
EPS actual | $2.96 |
EPS surprise | 3.86% |
Date | Price |
---|---|
Apr 25, 2025 | $437.44 |
Apr 28, 2025 | $433.99 |
Apr 29, 2025 | $436.97 |
Apr 30, 2025 | $432.65 |
May 01, 2025 | $471.38 |
May 02, 2025 | $471.90 |
May 05, 2025 | $475.07 |
May 06, 2025 | $473.71 |
May 07, 2025 | $486.61 |
4 days before | 7.76% |
4 days after | 3.23% |
On release day | 0.110% |
Change in period | 11.24% |
IDEXX Laboratories Earnings Call Transcript Summary of Q1 2025
IDEXX Laboratories Q1 2025 Earnings Call Summary for Investors
Leadership Present:
- Jay Mazelsky - President and CEO
- Andrew Emerson - EVP, CFO and Treasurer
- John Ravis - VP, Investor Relations
Financial Highlights:
- Revenue Growth: IDEXX reported a 5% organic revenue growth in Q1 2025. The growth was bolstered by:
- 4.5% increase in Companion Animal Group (CAG) Diagnostic recurring revenues.
- 7% organic growth in water and 4% in livestock, poultry, and dairy (LPD).
- Earnings Per Share (EPS): EPS was $2.96, a 5% increase as reported, and a 7% increase on a comparable basis.
- Operating Margins: Operating margins improved to an expected 31.1% to 31.6% for full-year guidance.
- Free Cash Flow: Q1 free cash flow was $208 million, with a trailing 12-month net income to free cash flow conversion ratio of 95%.
Operational Highlights:
- CAG Diagnostic Revenue: Achieved a 4.5% growth despite a 2.6% decline in U.S. clinical visits.
- Instruments: A total of 4,163 premium instruments were placed, down 13% year-over-year. However, IDEXX reported strong placement performance for new products like IDEXX inVue Dx.
- Innovations: The launch of IDEXX Cancer Dx for canine lymphoma has shown strong initial demand, with over 1,000 practices ordering the test within the month of launch. The inVue Dx is expected to transform point-of-care diagnostics and is currently ramping up production.
Market Environment:
- Veterinary Clinic Visits: Total U.S. clinical visits declined 2.6% overall, although diagnostic frequency during visits remains high.
- Pet Ownership Trends: Dog and cat ownership remains stable, with increased demand for pet care services likely to support long-term growth in diagnostics and other services.
- Tariffs and Supply Chain: IDEXX is navigating a dynamic tariff environment with less than 1% of revenues coming from China. The company has a strategy to maintain steady supply and minimize impacts from tariffs.
2025 Guidance:
- Revenue Projection: IDEXX updated revenue estimates to a range of $4.095 billion to $4.210 billion, reflecting a $40 million increase from previous forecasts due to improved foreign exchange conditions.
- Organic Growth Goals: The company reaffirmed organic revenue growth targets of 6% to 9% for the year, with specific gains in CAG Diagnostic recurring revenues.
- EPS Forecast: Revised EPS guidance is set between $11.93 and $12.43, factoring in previous litigation expense adjustments and foreign exchange impacts.
Investor Insight:
- Future Growth Drivers: The successful launch of new diagnostic tools and expanding software capabilities are seen as key drivers of long-term growth.
- Focus on Innovation: Continued emphasis on R&D investments, including enhancements in diagnostic technology, to leverage high pet ownership rates and evolving veterinary care demands.
- Commercial Strategy: Strong ongoing focus on customer retention and engagement, enhancing diagnostic utilization, and maintaining high-quality service to ensure continued revenue streams.
This summary captures the essential details from the earnings call for potential investors. Monitoring ongoing macroeconomic conditions, customer engagement, and IDEXX's product innovation trajectory will be crucial for understanding future performance.
IDEXX Laboratories Earnings History
Earnings Calendar
FAQ
When is the earnings report for IDXX?
IDEXX Laboratories (IDXX) has scheduled its earnings report for Aug 05, 2025 before the markets open.
What is the IDXX price-to-earnings (P/E) ratio?
IDXX P/E ratio as of May 16, 2025 (TTM) is 46.94.
What is the IDXX EPS forecast?
The forecasted EPS (Earnings Per Share) for IDEXX Laboratories (IDXX) for the first fiscal quarter 2025 is $3.29.
What are IDEXX Laboratories's retained earnings?
On its balance sheet, IDEXX Laboratories reported retained earnings of $998.43 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.